Skip to main content

People In The News: Jun 8, 2012

NEW YORK (GenomeWeb News) – Bruker has named Charles Wagner to be its new executive VP and chief financial officer, beginning at the end of June, Bruker said this week. Current CFO William Knight will continue to serve on the company's management team and will work with Wagner to ensure a smooth transition. Wagner also has stepped down from his positions on Bruker's board of directors and its audit committee, where he has served since 2010.

Wagner formerly was VP and CFO of Millipore, and he has 20 years of experience working in financial management, including most recently as executive VP of finance and administration and CFO of Progress Software.

Chris van Ingen, an independent director at Bruker, has been elected to take over Wagner's position on the audit committee.


Carl Gordon has resigned from his position on Complete Genomics' board of directors, effective immediately, the company stated in a filing with the US Securities and Exchange Commission. According to the company, Gordon said his resignation is not due to a disagreement with the company related to operations, policies, or practices.


Pharmacogenomic testing company Genelex has appointed Len Lewandowski to be director of sales. Lewandowski has over two decades of experience developing medical product and service field teams.


The Jackson Laboratory has started hiring administrators for the Jax Genomic Medicine translational research facility it plans to build in Farmington, Conn., the lab said this week. Carol O'Brien has been named senior human resources manager, and Mary Moquin has been hired to be a senior financial analyst responsible for developing and reviewing financial systems. Currently, O'Brien and Moquin are working in the lab's temporary facility, a renovated 9,700 square-foot space in an administrative building at the UConn Health Center campus, where at least 21 employees will be housed by the end of this year.


Abbott stated in an SEC filing this week that it has named Brian Blaser its new executive VP of diagnostic products. He is replacing Edward Michael, whose retirement will become effective June 30.


Rosetta Genomics has named Roy Davis to serve on its board of directors. Davis spent 27 years with Johnson & Johnson, including serving as president of J&J Development Corporation and VP of corporate development for the entire company, before he retired earlier this year. He also was worldwide franchise chairman of J&J's Ortho Clinical Diagnostics, Veridex, and Therakos.


Verinata Health CEO Caren Mason has resigned but will continue to provide the company with consultative services. Mason joined Verinata in November 2010. She was previously the president and CEO of Quidel, president and CEO of MiraMedica, CEO of eMed Technologies, and general manager of GE Healthcare.

Mason came out of retirement to join Verinata and her departure was planned, the company said. The firm plans to recruit a new CEO.


Paul Maier, Sequenom's chief financial officer, has been appointed to Apricus Biosciences' board of directors. Prior to joining Sequenom, Maier was senior vice president and chief financial officer of Ligand Pharmaceuticals and also held various roles at ICN Pharmaceuticals.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.